AU5745601A - A core formulation - Google Patents

A core formulation

Info

Publication number
AU5745601A
AU5745601A AU5745601A AU5745601A AU5745601A AU 5745601 A AU5745601 A AU 5745601A AU 5745601 A AU5745601 A AU 5745601A AU 5745601 A AU5745601 A AU 5745601A AU 5745601 A AU5745601 A AU 5745601A
Authority
AU
Australia
Prior art keywords
core formulation
rosiglitazone
core
formulation
biguanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5745601A
Other languages
English (en)
Inventor
Anthony J Cutie
Akwete L Adjei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeropharm Technology LLC
Original Assignee
Aeropharm Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology LLC filed Critical Aeropharm Technology LLC
Publication of AU5745601A publication Critical patent/AU5745601A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
AU5745601A 2000-05-01 2001-05-01 A core formulation Pending AU5745601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20156700P 2000-05-01 2000-05-01
US70233200A 2000-10-31 2000-10-31
PCT/US2001/013988 WO2001082867A2 (en) 2000-05-01 2001-05-01 A core formulation

Publications (1)

Publication Number Publication Date
AU5745601A true AU5745601A (en) 2001-11-12

Family

ID=26896877

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5745601A Pending AU5745601A (en) 2000-05-01 2001-05-01 A core formulation
AU2001257456A Ceased AU2001257456B2 (en) 2000-05-01 2001-05-01 A core formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001257456A Ceased AU2001257456B2 (en) 2000-05-01 2001-05-01 A core formulation

Country Status (8)

Country Link
EP (1) EP1278513B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004516234A (cg-RX-API-DMAC7.html)
AT (1) ATE367151T1 (cg-RX-API-DMAC7.html)
AU (2) AU5745601A (cg-RX-API-DMAC7.html)
CA (1) CA2407713A1 (cg-RX-API-DMAC7.html)
DE (1) DE60129425T2 (cg-RX-API-DMAC7.html)
ES (1) ES2290130T3 (cg-RX-API-DMAC7.html)
WO (1) WO2001082867A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192749B (cg-RX-API-DMAC7.html) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
RU2567032C2 (ru) * 2009-05-01 2015-10-27 Апталис Фарматек, Инк. Перорально распадающиеся таблеточные композиции, содержащие комбинации неопиоидных и опиоидных анальгетиков

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
ES2052369T3 (es) * 1990-01-30 1994-07-01 Akzo Nv Articulo para el suministro controlado de una sustancia activa, que comprende un espacio hueco completamente cerrado por una pared y lleno en su totalidad o en parte con una o mas sustancias activas.
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TR199903057T2 (xx) * 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use

Also Published As

Publication number Publication date
WO2001082867A2 (en) 2001-11-08
ATE367151T1 (de) 2007-08-15
JP2004516234A (ja) 2004-06-03
CA2407713A1 (en) 2001-11-08
DE60129425T2 (de) 2008-04-17
WO2001082867A3 (en) 2002-03-07
EP1278513A4 (en) 2005-01-26
ES2290130T3 (es) 2008-02-16
AU2001257456B2 (en) 2006-02-09
EP1278513B1 (en) 2007-07-18
DE60129425D1 (de) 2007-08-30
EP1278513A2 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
WO2001082875A3 (en) A core formulation
MXPA02007285A (es) Recubrimiento de poliuretano fotocromico y productos que contienen dicho recubrimiento.
ZA200203368B (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide.
PL360473A1 (en) Hydrophilic coating including dlc on substrate
MXPA03003853A (es) Abastecedor de medicamentos.
ZA200204147B (en) Aerosol composition comprising formoterol.
EP1344780A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
WO2001035941A8 (en) Novel composition based on a thiazolidinedione and metformin and use
ZA200300791B (en) Confectionery product containing active ingredients.
HUP0204101A3 (en) 3-aminoquinazolin-2,4-dione antibacterial agents, pharmaceutical compositions containing them and their use
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
HUP0102968A3 (en) Coated candy product
MXPA03008655A (es) Articulos que contienen un agente refrescante sin olor a menta.
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
MXPA02005223A (es) Derivados y analogos de fenilo trisustituido novedosos.
EP1278513A4 (en) CORE FORMULATION
WO2001082874A3 (en) A medicinal aerosol formulation
MXPA02011490A (es) Composicion de revestimiento en polvo, metodo de su uso y los articulos formados de la misma.
ZA200400092B (en) Product manufacturing line.
AU2001237025A1 (en) Antimicrobial composition and articles
AU4961899A (en) Hygienic article comprising oil resistant, hydrophilic adhesive
ITTO20000465A0 (it) Confezione per articoli igienico-sanitari e relativo procedimento di fabbricazione.
WO2002022074A3 (fr) Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale